Rheumatology infusion suite software: scheduling, inventory and chair utilisation
An infusion suite is the only part of a rheumatology practice where the operational problem and the financial one are the same problem. A chair sits empty, or a vial gets opened and partly thrown away.
Rheumatology infusion suite software has to hold three things at once: a chair and nurse schedule, a drug inventory the practice purchased, and the documentation that supports billing for both the administration and the drug. Medicare pays most separately payable Part B drugs at 106 per cent of ASP, so margin is thin and waste is visible.
Buy-and-bill makes a rheumatology practice a small pharmacy with a waiting room attached.
The practice purchases the biologic, stores it, schedules a patient into a chair, administers it, and bills afterwards. Every step in that chain can go wrong in a way that costs real money, and most practice management systems were not designed with any of it in mind.
The rules that govern the money are published and specific. Knowing them changes what you ask the software to do.
What Medicare actually pays, and why margin is thin
Start with the payment basis, because it sets how much room there is for anything to go wrong.
CMS states the rule plainly on its average sales price page: most separately payable drugs and biological products have a payment limit of the average sales price plus 6 per cent. The Medicare Claims Processing Manual puts the same rule as 106 per cent of ASP, and traces it to section 1847A of the Social Security Act.
Sequestration then reduces Medicare payment by 2 per cent, restored to its original statutory rate on 1 July 2022. You will see an effective percentage quoted in trade material that combines the two. We are not printing one, because CMS does not publish a combined figure and the arithmetic depends on assumptions about the beneficiary share. Know the two rules separately and let your finance people combine them.
Biosimilars are paid differently and the difference is worth knowing before you stock one: the biosimilar’s own ASP plus 6 per cent of the reference product’s ASP, or plus 8 per cent for qualifying biosimilars.
Discarded drug billing: JW, JZ, and the modifier that is mandatory
This is where an infusion suite most often leaks money, and the rule is not optional.
CMS’s discarded drugs page sets out both modifiers. JW goes on claims for discarded amounts from single-dose containers or single-use packages separately payable under Part B, alongside the claim for the administered amount. JZ is required on all claims billing for drugs from single-dose containers or single-use packages that are separately payable under Part B when there are no discarded amounts.
Read that again: JZ is required when nothing was wasted. A practice that uses JW correctly and never uses JZ is not compliant. CMS’s MLN article on the JZ modifier gives the descriptors as “drug amount discarded/not administered to any patient” for JW and “zero drug amount discarded/not administered to any patient” for JZ, with JZ required from July 2023 and claims editing beginning in October 2023.
- JZ is not a waste modifier. It is a no-waste modifier, and it is mandatory. If your infusion workflow only prompts staff when something was discarded, it is prompting on the wrong half of the cases.
Safe injection practices and what the software should force
The clinical rules here are unambiguous and several of them have direct consequences for how a vial is tracked.
CDC’s safe injection practices guidance states that single-dose vials should be used for parenteral medications wherever possible, and that medications from single-dose vials or ampules must not be administered to multiple patients or have leftover contents combined for later use. Where multidose vials must be used, both the needle or cannula and the syringe used to access the vial must be sterile, and multidose vials should not be kept in the immediate patient treatment area.
Those two facts together are why single-dose waste exists at all, and why the discarded amount is a clinical number before it is a billing one. A system that records the administered dose but not the vial size cannot produce the discarded figure without someone doing arithmetic by hand.
Compounding rules, and a carve-out worth knowing
Practices are sometimes told that preparing an infusion in the office triggers the full weight of pharmacy compounding regulation. That is not what FDA says.
FDA’s guidance on insanitary conditions at compounding facilities, November 2020, states that FDA generally does not intend to take action under the relevant adulteration provision against a physician compounding a drug product where that production occurs in the physician’s office for in-office administration. The guidance is aimed at pharmacies, federal facilities and outsourcing facilities.
USP General Chapter <797> is a different animal and is frequently misdescribed. USP is a private standards-setting organisation. Chapter <797> is not a federal regulation; it becomes enforceable through state boards of pharmacy, FDA’s statutory references and accreditors. USP itself reports that at least 87 per cent of boards of pharmacy either require full compliance with <797> or incorporate it into state regulations. So it very probably applies to you, by a route that is not federal law, and the details are a question for New Jersey rather than for Washington. This is the kind of distinction worth settling during a compliance review rather than in an argument with a surveyor.
Chairs full but the numbers not working?
We trace how your infusion suite schedules chairs, tracks drug and documents waste, and hand you written findings on where the money goes.
Biosimilar substitution and what it does to inventory
The interchangeability picture moved twice recently, and a lot of circulating guidance is out of date.
FDA’s page on biosimilars and interchangeable biosimilars states that an interchangeable biosimilar may, depending on state pharmacy laws, be substituted for the reference product at the pharmacy without the intervention of the prescribing health care professional, and that biosimilars and interchangeable biosimilars are as safe and effective as the reference product. FDA has also said it now generally does not recommend switching studies, a reversal of its earlier position.
Two things follow for an infusion suite. First, the substitution right FDA describes is a pharmacy substitution right governed by state law; it is not a rule about what a clinic stocks. Second, because payment for a biosimilar is calculated from its own ASP, stocking decisions have a financial consequence that a reference-product-only inventory does not expose. Your system needs to distinguish products at the level the claim does, which in practice means the specific billing code and not the molecule.
Chair utilisation, which is the operational half
None of the above helps if the chairs sit empty, and chair utilisation is the number most practices cannot produce on demand.
The constraint is rarely the chair on its own. It is the chair plus a nurse plus a drug that has to be on hand, and those three have different lead times. Scheduling software that books chairs without knowing whether the drug has arrived produces a schedule that looks full and runs short. Capturing the three together is the whole design requirement, and it usually means the infusion schedule has to live where the clinical record lives rather than beside it, which is ordinary EHR workflow optimization work.
- Capture vial size, not just dose. Waste is arithmetic you should not do by hand.
- Prompt for JZ, not only JW. The no-waste case is the mandatory one.
- Track products at billing-code level. Biosimilars are paid on their own ASP.
- Schedule the drug with the chair. A full schedule with no stock is not a full schedule.
Qventive provides rheumatology infusion suite software services for New Jersey practices, normally as part of IT support for rheumatology practices rather than as a standalone project.
Where the infusion workflow depends on how the clinical system is configured, that work runs through rheumatology EHR and IT support, and the inventory and ordering paths should appear in your HIPAA risk analysis alongside everything else that leaves the building.
Infusion suites: common questions
How does Medicare pay for the drug in a buy-and-bill infusion suite?
When do we use the JW modifier and when do we use JZ?
Do office infusion preparation rules count as compounding?
What are the HIPAA implications of an infusion suite?
How do we measure chair utilisation properly?
Let’s meet
Qventive supports rheumatology and infusion practices across New Jersey. Thirty years healthcare-exclusive, from our office in Hackensack.
- Most separately payable drugs and biological products have a payment limit of ASP plus 6 per cent. cms.gov
- JW for discarded amounts; JZ required on all claims for single-dose containers with no discarded amounts. cms.gov
- Use single-dose vials wherever possible; do not administer from single-dose vials to multiple patients or combine leftover contents. cdc.gov
- FDA generally does not intend to act against a physician compounding in the physician’s office for in-office administration. fda.gov
- An interchangeable biosimilar may, depending on state pharmacy laws, be substituted at the pharmacy without prescriber intervention. fda.gov